<a href="https://laohu8.com/S/BLTE">Belite Bio</a>'s drug for genetic eye disease meets main goal in late-stage trial Dec 1 (Reuters) - Belite Bio BLTE.O said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。